Diffuse large B-cell lymphoma – Life with Disease

Go back

Diffuse large B-cell lymphoma (DLBCL) is an aggressive blood cancer that starts when healthy infection-fighting B cells change and grow out of control. It is the most common type of non-Hodgkin lymphoma, affecting thousands of people each year. While DLBCL grows quickly, it often responds well to treatment, and many patients can be cured—especially when the condition is detected and treated early.

Understanding the Prognosis

The outlook for people with diffuse large B-cell lymphoma can feel overwhelming at first, but it’s important to know that many patients respond very well to treatment. About 75% of people who receive standard chemotherapy-based therapy initially achieve good results, and a significant number of patients are cured of the disease entirely.[7] The prognosis depends on several factors, including how quickly treatment begins and the specific characteristics of your disease.

Between 50% and 60% of all patients are cured with rituximab-based chemoimmunotherapy, which is a combination of targeted medication and chemotherapy drugs, in the first-line setting.[11] This means that more than half of patients treated with this approach will never experience the disease again. For those whose cancer does come back, newer treatment options—including CAR T-cell therapy (a treatment that uses modified immune cells) and other novel medications—have improved outcomes significantly in recent years.

Doctors use something called the International Prognostic Index (IPI) to help predict how well your disease might respond to treatment. This scoring system looks at factors like your age, blood test results showing a substance called lactate dehydrogenase, how far the cancer has spread, your physical condition, and whether the cancer has appeared in areas outside the lymph nodes.[16] Patients with lower IPI scores—meaning fewer concerning factors—generally have better outcomes, while those with higher scores may need more intensive treatment approaches.

⚠️ Important
Although DLBCL is aggressive and fast-growing, this also means it often responds quickly to treatment. Your individual prognosis depends on many personal factors, and your healthcare team can provide the most accurate information based on your specific situation. Early diagnosis and immediate treatment significantly improve outcomes.

For patients whose disease comes back or doesn’t respond to initial treatment (called relapsed or refractory disease), roughly 30% to 40% still have the potential to be cured with CAR T-cell therapy.[12] This represents a major advance in treatment, giving hope to patients even when first-line therapy doesn’t work as planned.

Natural Progression Without Treatment

Diffuse large B-cell lymphoma is considered a fast-growing cancer, which means it progresses rapidly if left untreated. Without treatment, the abnormal B cells continue to multiply at an accelerated rate, overtaking healthy cells in the lymphatic system and potentially spreading to other organs throughout the body.[2] These cancerous cells are larger than normal B cells and spread out in a diffuse pattern through tissues, which is how the disease gets its name.

Because DLBCL affects the immune system, untreated disease means your body loses its ability to fight off infections properly. The abnormal B cells can no longer perform their normal function of creating antibodies to combat viruses and bacteria.[2] As the cancer progresses, it can appear not only in lymph nodes but virtually anywhere in the body—including the gastrointestinal tract, thyroid, skin, breast, bone, brain, stomach, liver, intestines, bone marrow, or kidneys.[7]

The rapid growth characteristic of DLBCL means that symptoms can start or worsen in just a few weeks.[5] Swollen lymph nodes may grow very quickly, and general symptoms like fever, night sweats, and weight loss can become more severe. Without intervention, the disease continues to spread and compromise more of the body’s systems, making treatment more difficult and outcomes less favorable. This is why immediate treatment is strongly recommended once DLBCL is diagnosed.

Possible Complications

Diffuse large B-cell lymphoma can lead to various complications, both from the disease itself and from its treatments. One serious complication is when the cancer spreads to the central nervous system, involving the brain or spinal cord.[3] This is called secondary DLBCL of the CNS and occurs when lymphoma cells move into these areas at a later time, even if the disease didn’t start there. Some patients are at higher risk for this complication and may need special preventive treatments.

Because DLBCL weakens the immune system, patients become more vulnerable to serious infections. The cancerous B cells can’t fight off disease-causing organisms effectively, leaving the body defenseless against viruses, bacteria, and other pathogens. Viral infections and decreased blood cell counts are complications reported in patients receiving treatment.[14] These infections can become life-threatening if not addressed promptly.

Treatment itself can cause complications. Chemotherapy may lead to decreased counts of white blood cells, red blood cells, and platelets, which affects the body’s ability to fight infection, carry oxygen, and stop bleeding.[14] Lung disorders and heart disorders have been reported, particularly in elderly patients receiving combination chemotherapy. Some patients experience severe infusion-related reactions during medication administration, which can include hives, swelling, difficulty breathing, chest pain, and dizziness.[14]

Another potential complication is hepatitis B virus reactivation. If you have previously had hepatitis B infection, the virus can become active again during or after DLBCL treatment, potentially causing serious liver problems.[14] This is why doctors test for hepatitis B before starting treatment. Severe skin and mouth reactions are also possible, including painful sores, ulcers, blisters, peeling skin, rashes, and pustules that can appear at any time during treatment.[14]

Impact on Daily Life

Living with diffuse large B-cell lymphoma affects nearly every aspect of daily life—physically, emotionally, socially, and practically. The most noticeable physical changes often include profound fatigue that goes beyond normal tiredness. Many patients describe feeling exhausted even after rest, which can make previously simple tasks like climbing stairs, preparing meals, or running errands feel overwhelming.[7] This debilitating fatigue isn’t just being tired; it’s an all-consuming lack of energy that can persist throughout treatment and recovery.

Physical symptoms like swollen lymph nodes, shortness of breath, and sudden weight loss can make it difficult to maintain normal activities.[2] Some patients experience pain at the site of enlarged lymph nodes or masses, while others notice their clothes fitting differently around the neck, armpits, or groin where swelling occurs. If the lymphoma affects the chest area, you might feel breathless during conversations or while lying down, which can interfere with sleep and daily activities.

Work and professional life often require significant adjustments. Many patients need to take extended time off for treatment, which typically involves cycles of chemotherapy every 14 or 21 days for about six months.[14] The side effects of treatment—including nausea, increased risk of infection, and extreme tiredness—can make it impossible to maintain regular work schedules. Some patients eventually retire due to the physical and emotional demands of the disease and its treatment.

The emotional impact can be just as profound as the physical challenges. Learning you have an aggressive cancer is shocking and frightening. Many patients experience anxiety about their prognosis, fear about treatment side effects, and worry about how their illness affects loved ones. Mental health challenges are common, and some patients are diagnosed with conditions like PTSD (post-traumatic stress disorder) after experiencing relapses or difficult treatments.[17] Anger, grief, and a sense of loss for your previous healthy life are all normal reactions.

Social relationships and activities often change during treatment. Because chemotherapy weakens the immune system, patients must be careful about avoiding crowds and people who are sick. This means missing social gatherings, family celebrations, and normal interactions with friends. Hobbies and leisure activities may need to be put on hold, especially those requiring physical energy or exposing you to potential infections. The isolation this creates can feel lonely and disconnecting.

Practical matters like managing finances, navigating insurance coverage, coordinating appointments, and arranging transportation to treatment centers add stress to an already difficult situation. Some patients need help with basic household tasks, personal care, and managing medications. The inability to drive during certain treatments or when feeling unwell means relying on others for transportation, which can feel like a loss of independence.

Despite these challenges, many patients find ways to adapt and cope. Breaking tasks into smaller, manageable pieces helps conserve energy. Accepting help from family and friends—whether it’s preparing meals, driving to appointments, or simply providing company—can make the burden feel lighter. Connecting with other patients through support groups, either in person or online, provides understanding from people who truly know what you’re experiencing. Professional counseling or therapy can help process the complex emotions that come with cancer diagnosis and treatment.

⚠️ Important
The emotional and mental health aspects of living with DLBCL are just as important as physical treatment. Don’t hesitate to ask your healthcare team about resources for psychological support, including counseling services, support groups, and psychiatric care if needed. Taking care of your mental health is part of comprehensive cancer care.

Support for Family Members

When someone is diagnosed with diffuse large B-cell lymphoma, the entire family is affected. Family members often feel helpless, wanting desperately to fix the situation but unable to do so.[17] Understanding how to provide meaningful support, particularly when it comes to clinical trials and treatment decisions, is crucial for families navigating this difficult journey together.

Clinical trials represent an important option for many DLBCL patients, especially those with higher-risk disease or those whose cancer has returned. These research studies test new treatments, combinations of drugs, or different approaches to managing the disease. Families should understand that clinical trials have strict eligibility requirements and may not be appropriate for every patient, but they can provide access to cutting-edge treatments before they become widely available.

Family members can help by researching clinical trial options alongside the patient. Many organizations, including the Lymphoma Research Foundation, maintain databases of active trials specifically for DLBCL.[3] When you find potentially relevant trials, help organize the information—print out descriptions, note eligibility criteria, and prepare questions to ask the medical team. Sometimes a fresh pair of eyes can spot opportunities or details that an overwhelmed patient might miss.

Preparing for medical appointments is one of the most practical ways families can assist. The volume of information during cancer treatment can be overwhelming, and patients may struggle to remember everything discussed. Attend appointments when possible and take notes about what doctors say regarding trial options, treatment plans, and next steps. Help prepare questions beforehand—write them down so nothing important gets forgotten in the stress of the consultation.

Transportation and logistics are significant challenges during treatment. Chemotherapy cycles typically occur every few weeks over several months, and some treatments require daily visits for several days in a row. Clinical trials may involve additional appointments, extra testing, and travel to specialized centers. Family members can coordinate rides, help manage the treatment calendar, and ensure the patient gets to appointments safely and on time.

Understanding the practical aspects of clinical trial participation helps families support informed decision-making. Trials have phases that test different aspects of treatment—some compare new drugs to standard treatment, while others test entirely experimental approaches. Help the patient understand what participation would involve: how often they’d need to come in, what side effects might occur, whether there are costs involved, and what happens if the trial treatment doesn’t work. Having honest conversations about these realities helps everyone make decisions together.

Emotional support during the trial decision process is equally important. Patients may feel pressure to try something experimental out of desperation, or conversely, they may feel guilty about not pursuing every possible option. Family members can help by listening without judgment, validating fears and concerns, and reminding patients that the right choice is the one that aligns with their values and goals. Sometimes the best support is simply sitting with uncertainty together and acknowledging that there are no perfect answers.

Financial and insurance navigation often falls partially on family members. Clinical trials typically cover the costs of the experimental treatment itself, but other aspects of care may still incur expenses. Families can help by communicating with insurance companies, understanding what’s covered, investigating financial assistance programs, and helping manage medical bills. This practical support removes burden from patients who need to focus their energy on healing.

Remember that caregiving takes a toll on family members too. You can’t pour from an empty cup—taking care of yourself enables you to better support your loved one. Seek your own sources of support, whether through caregiver support groups, counseling, or simply making time for activities that replenish your energy. Setting realistic expectations about what you can do and accepting help from others prevents burnout during what may be a lengthy treatment journey.

💊 Registered drugs used for this disease

List of officially registered medicines that are used in the treatment of this condition, based only on the provided sources:

  • Rituximab (Rituxan and biosimilars) – A targeted therapy monoclonal antibody that is commonly combined with chemotherapy as the most widely used treatment for DLBCL
  • Cyclophosphamide (Procytox) – A chemotherapy drug used as part of the R-CHOP combination regimen
  • Doxorubicin (Adriamycin) – A chemotherapy drug included in the R-CHOP combination for treating DLBCL
  • Vincristine (Oncovin) – A chemotherapy drug used in the R-CHOP regimen
  • Prednisone – A corticosteroid included in the R-CHOP combination treatment
  • Polatuzumab vedotin-piiq (Polivy) – An antibody drug conjugate approved for use in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) for intermediate- to high-risk DLBCL
  • Etoposide (Vepesid, Toposar, Etopophos) – A chemotherapy drug sometimes added to R-CHOP to create the R-CHOEP or R-EPOCH regimens
  • Bendamustine (Treanda) – Used in combination with rituximab for relapsed or refractory DLBCL
  • Lenalidomide (Revlimid) – Used with rituximab or tafasitamab for relapsed/refractory disease
  • Tafasitamab-cxix (Monjuvi) – Approved for relapsed or refractory DLBCL
  • Axicabtagene ciloleucel (Yescarta) – A CAR T-cell therapy approved as second-line treatment for DLBCL with demonstrated overall survival benefit
  • Lisocabtagene maraleucel (Breyanzi) – A CAR T-cell therapy approved for relapsed/refractory DLBCL with lower rates of severe side effects
  • Tisagenlecleucel (Kymriah) – A CAR T-cell therapy approved for relapsed or refractory DLBCL
  • Loncastuximab tesirine – An antibody drug conjugate targeting CD19 for relapsed/refractory disease
  • Epcoritamab-bysp (Epkinly) – A CD20-directed bispecific antibody for relapsed/refractory DLBCL
  • Glofitamab-gxbm (Columvi) – A CD20-directed bispecific antibody for relapsed/refractory DLBCL
  • Selinexor (Xpovio) – Approved for relapsed or refractory DLBCL
  • Pembrolizumab (Keytruda) – Used for relapsed/refractory primary mediastinal large B-cell lymphoma, a subtype of DLBCL
  • Ibrutinib (Imbruvica) – A targeted therapy being studied for certain DLBCL subtypes, particularly the ABC subtype

Ongoing Clinical Trials on Diffuse large B-cell lymphoma

  • Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

    Recruiting

    1 1 1
    Germany
  • Study Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Belgium Germany Ireland Italy Poland
  • Study of Epcoritamab, Lenalidomide, and Rituximab for Patients with Relapsed and Refractory Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

    Recruiting

    1 1 1 1
    France
  • Study of Zilovertamab Vedotin and Drug Combination for Untreated Diffuse Large B-Cell Lymphoma Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Belgium Denmark France Greece Hungary Italy +5
  • Study of Rituximab and Golcadomide for Older Frail Patients with Diffuse Large B-cell Lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy
  • Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Austria Germany
  • Study on Golcadomide and Valemetostat Tosylate for Patients with Relapsed or Refractory Non-Hodgkin Lymphomas

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark France Italy Spain
  • Study on Golcadomide for Patients with Relapsed or Refractory Aggressive Large B-Cell Lymphoma at High Risk of Relapse After CAR T-Cell Therapy

    Recruiting

    1 1 1
    Investigated diseases:
    France
  • Study on Preventing Heart Problems in Patients with Diffuse Large B-Cell Lymphoma Using Dexrazoxane and a Drug Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    The Netherlands
  • Study on Acalabrutinib with Rituximab and Drug Combination for Older Adults with Untreated Diffuse Large B-Cell Lymphoma

    Recruiting

    1 1 1 1
    Germany Greece

References

https://www.mayoclinic.org/diseases-conditions/diffuse-large-b-cell-lymphoma/symptoms-causes/syc-20584636

https://my.clevelandclinic.org/health/diseases/24405-diffuse-large-b-cell-lymphoma

https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/dlbcl/

https://www.ncbi.nlm.nih.gov/books/NBK557796/

https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types/diffuse-large-b-cell-lymphoma

https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/diffuse-large-b-cell-lymphoma/

https://www.yalemedicine.org/conditions/diffuse-large-b-cell-lymphoma

https://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma

https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/dlbcl/dlbcltreatment/

https://www.mayoclinic.org/diseases-conditions/diagnosis-treatment/drc-20584653

https://pmc.ncbi.nlm.nih.gov/articles/PMC9843196/

https://consultqd.clevelandclinic.org/emerging-second–and-third-line-treatments-improve-outcomes-in-diffuse-large-b-cell-lymphoma

https://www.yalemedicine.org/conditions/diffuse-large-b-cell-lymphoma

https://www.rituxan.com/nhl/about-rituxan/diffuse-large-b-cell-lymphoma.html

https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/dlbcl/relapseddlbcl/

https://cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphoma/treatment/treatment-by-type/diffuse-large-b-cell-lymphoma

https://www.sobi.com/en/stories/living-diffuse-large-b-cell-lymphoma

https://my.clevelandclinic.org/health/diseases/24405-diffuse-large-b-cell-lymphoma

https://thepatientstory.com/patient-stories/non-hodgkin-lymphoma/diffuse-large-b-cell-lymphoma/

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

FAQ

Can diffuse large B-cell lymphoma be cured?

Yes, DLBCL can often be cured, especially when diagnosed and treated early. About 75% of patients initially respond well to standard chemotherapy-based therapy, and between 50% and 60% of all patients are cured with rituximab-based chemoimmunotherapy in the first-line setting. Even patients whose disease comes back have treatment options, including CAR T-cell therapy, which can cure 30% to 40% of relapsed patients.[7][11]

How quickly does DLBCL progress?

DLBCL is an aggressive, fast-growing lymphoma. Symptoms can start or worsen in just a few weeks, and swollen lymph nodes can grow very quickly. This rapid progression means that treatment usually needs to begin soon after diagnosis. However, the fact that it grows quickly also means it often responds rapidly to treatment.[5]

What is R-CHOP and how long does treatment take?

R-CHOP is the most common first-line treatment for DLBCL. It’s a combination of rituximab (a targeted therapy), cyclophosphamide, doxorubicin, vincristine, and prednisone. Treatment typically involves up to 6-8 cycles given every 21 days (once every three weeks), meaning most people complete their treatment in about six months. Each treatment day is followed by 20 days of rest and recovery.[9][14]

What is CAR T-cell therapy and when is it used?

CAR T-cell therapy is a type of immunotherapy where a patient’s own immune cells (T-cells) are collected, modified in a laboratory to recognize and attack cancer cells, then returned to the patient’s body. It’s approved as second-line therapy for DLBCL patients who don’t respond to initial treatment or whose cancer comes back. About 30-40% of patients treated with CAR T-cell therapy have the potential to be cured. Three approved CAR T-cell therapies for DLBCL are axicabtagene ciloleucel, lisocabtagene maraleucel, and tisagenlecleucel.[12][15]

Are there different types of DLBCL?

Yes, there are many subtypes of DLBCL classified based on genetic changes, where in the body the cancer starts, and whether certain viruses are involved. Common subtypes include primary mediastinal B-cell lymphoma (starting in the chest), primary CNS lymphoma (in the brain), EBV-positive DLBCL (associated with Epstein-Barr virus), and T-cell/histiocyte-rich large B-cell lymphoma. Most cases are classified as “DLBCL not otherwise specified” (DLBCL NOS) when they don’t fit into specific subcategories. Your subtype can affect treatment choices and outlook.[2][3]

What are the main side effects of DLBCL treatment?

Common side effects from R-CHOP and similar regimens include decreased blood cell counts (affecting infection risk, energy levels, and bleeding), extreme fatigue, nausea, hair loss, and increased vulnerability to infections. Infusion-related reactions during rituximab administration can include fever, chills, difficulty breathing, hives, and chest pain. Some patients experience lung or heart problems, particularly elderly patients. Most side effects are manageable with supportive care and medications, and your healthcare team will monitor you closely throughout treatment.[14]

🎯 Key takeaways

  • DLBCL is aggressive but often curable—between 50-60% of patients are cured with first-line treatment, and the majority respond well to therapy.
  • Fast growth means fast response—while DLBCL progresses quickly, this same characteristic makes it highly responsive to chemotherapy and other treatments.
  • R-CHOP remains the gold standard—this combination of rituximab and four chemotherapy drugs has been successfully treating DLBCL for years with proven results.
  • CAR T-cell therapy offers hope for relapse—roughly 30-40% of patients whose disease returns can still be cured with this innovative immunotherapy approach.
  • Multiple subtypes exist with different behaviors—over a dozen subtypes have been identified, each with unique genetic features affecting treatment response.
  • New treatments keep emerging—bispecific antibodies, antibody drug conjugates like polatuzumab vedotin, and other novel therapies continue expanding treatment options.
  • The International Prognostic Index predicts outcomes—this scoring system helps doctors customize treatment intensity based on individual risk factors.
  • DLBCL can appear anywhere in the body—beyond lymph nodes, it may affect organs like the stomach, brain, skin, bones, or virtually any tissue.